<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282070</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-I-103</org_study_id>
    <nct_id>NCT04282070</nct_id>
  </id_info>
  <brief_title>SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase Ib, Open-label Trial to Investigate the Safety and Tolerability of SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic&#xD;
      nasopharyngeal carcinoma(R/M NPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to assess the safety and tolerability of SHR-1701 in&#xD;
      patients with R/M NPC. The secondary purpose is to assess the anti-tumor activity and&#xD;
      immunogenicity of SHR-1701 in R/M NPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity Toxicity</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of participants with adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per RECIST 1.1</measure>
    <time_frame>up to 2 years</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least 30% decrease in the sum of diameters of target lesions) per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per RECIST 1.1</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) per RECIST 1.1</measure>
    <time_frame>up to 2 years</time_frame>
    <description>DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SHR-1701</measure>
    <time_frame>up to 2 years</time_frame>
    <description>anti SHR-1603 antibodies (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall Survival is defined as the time from registration to death due to any cause, or censored at date last known alive. OS will be measured by the Method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>SHR-1701 (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1701 for R/M NPC failure after platinum-based chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1701 (Arm B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1701 for R/M NPC failure after anti PD-1/PD-L1 antibody therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1701 plus Gemcitabine and Cisplatin (Arm C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1701+Gemcitabine+Cisplatin for first line treatment of R/M NPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1701 plus Albumin Paclitaxel (Arm D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1701+Albumin Paclitaxel for R/M NPC failure after first line anti PD-1/PD-L1 antibody therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701</intervention_name>
    <description>Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.</description>
    <arm_group_label>SHR-1701 (Arm A)</arm_group_label>
    <arm_group_label>SHR-1701 (Arm B)</arm_group_label>
    <arm_group_label>SHR-1701 plus Albumin Paclitaxel (Arm D)</arm_group_label>
    <arm_group_label>SHR-1701 plus Gemcitabine and Cisplatin (Arm C)</arm_group_label>
    <other_name>SHR-1701 Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Maximum 6 cycles for combined therapy.</description>
    <arm_group_label>SHR-1701 plus Gemcitabine and Cisplatin (Arm C)</arm_group_label>
    <other_name>Gemcitabine Hydrochloride for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Maximum 6 cycles for combined therapy.</description>
    <arm_group_label>SHR-1701 plus Gemcitabine and Cisplatin (Arm C)</arm_group_label>
    <other_name>Cisplatin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin Paclitaxel</intervention_name>
    <description>Maximum 6 cycles for combined therapy.</description>
    <arm_group_label>SHR-1701 plus Albumin Paclitaxel (Arm D)</arm_group_label>
    <other_name>nab-Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed Recurrent/Metastatic Nasopharyngeal Carcinoma&#xD;
&#xD;
          -  Subjects failure after platinum-based chemotherapy; failure from anti-PD-1/PD-L1&#xD;
             antibody therapy; Primarily metastatic (stage IVB as defined by the International&#xD;
             Union against Cancer and American Joint Committee on Cancer staging system for NPC,&#xD;
             eighth edition) or recurrent NPC that is not amenable for local regional treatment or&#xD;
             curative treatment; failure from first line anti-PD-1/PD-L1 antibody therapy.&#xD;
&#xD;
          -  Able and willing to provide signed informed consent form, and able to comply with all&#xD;
             procedures.&#xD;
&#xD;
          -  Histologically or cytologically proven metastatic or locally advanced solid tumors.&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks as judged by the Investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry.&#xD;
&#xD;
          -  Disease must be measurable with at least 1 uni dimensional measurable lesion by&#xD;
             Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function as defined in the protocol Other&#xD;
             protocol-defined inclusion criteria could apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with an anti-PD1, anti-PD-L1, anti-CTLA-4 or a TGFb inhibitor.&#xD;
&#xD;
          -  Anticancer treatment within 28 days before the first dose of study drug.&#xD;
&#xD;
          -  Major surgery within 28 days before start of trial treatment.&#xD;
&#xD;
          -  Systemic therapy with immunosuppressive agents within 7 days prior to the first dose&#xD;
             of study drug; or use any investigational drug within 28 days before the start of&#xD;
             trial treatment.&#xD;
&#xD;
          -  With any active autoimmune disease or history of autoimmune disease.&#xD;
&#xD;
          -  With active central nervous system (CNS) metastases causing clinical symptoms or&#xD;
             requiring therapeutic intervention.&#xD;
&#xD;
          -  Clinically significant cardiovascular and cerebrovascular diseases&#xD;
&#xD;
          -  History of immunodeficiency including seropositive for human immunodeficiency virus&#xD;
             (HIV), or other acquired or congenital immunedeficient disease, or any active systemic&#xD;
             viral infection requiring therapy.&#xD;
&#xD;
          -  Previous malignant disease (other than the target malignancy to be investigated in the&#xD;
             trial) within the last 2 years. Subjects with history of cervical carcinoma in situ,&#xD;
             superficial or non-invasive bladder cancer or basal cell or squamous cell cancer in&#xD;
             situ previously treated with curative intent are NOT excluded.&#xD;
&#xD;
          -  Receipt of any organ transplantation, including allogeneic stem-cell transplantation&#xD;
             Other protocol-defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qing Yang, MD</last_name>
    <phone>+86-021-61052512</phone>
    <email>yangqing@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital of Guangzhou Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, M.D.</last_name>
      <phone>+86 020-87342288</phone>
      <email>zhangli6@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

